Efficacy of COPE-A for PTSD and SUD in Young People Demonstrated in RCT
The COPE-A treatment showed significantly greater reductions in PTSD symptom severity compared to supportive counseling at 4 months, with effects maintained at 12 months.
Asset / Drug
Drug and asset intelligence for Efficacy with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The study evaluates the efficacy and safety of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer across different altitudes.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.